Skip to main content
NANS 2026 Annual Meeting Main banner

    Tim Denison, PhD

    Royal Academy of Engineering Chair in Emerging Technologies
    Institute of Biomedical Engineering, University of Oxford
    Oxford, United Kingdom

    Professor Denison holds a joint appointment in Engineering Science and Clinical Neurosciences at Oxford, where he explores the fundamentals of physiologic closed-loop systems. Tim also serves as an advisor to several governments and industry boards for translational medical devices; in particular, helping define strategies for mapping scientific discovery to product development roadmaps within the regulatory and economic constraints of medical systems. To support translation to the clinic, he is a director and chief engineer of Amber Therapeutics, which designs, manufactures, and distributes the Picostim-DyNeuMo investigational research system that is active in multiple first-in-human device trials. Prior to Oxford, Tim was a Technical and Bakken Fellow at Medtronic PLC and Vice President of Research & Core Technology for the Restorative Therapies Group, where he helped oversee the design of next generation neural interface and algorithm technologies for the treatment of chronic neurological disease. In 2015, he was elected to the College of Fellows for the American Institute of Medical and Biological Engineering (AIMBE), and in 2024, he was named a Fellow of the Royal Academy of Engineering. He has an MS and PhD from MIT in electrical engineering, an AB in Physics and MBA from the University of Chicago.

    Presentation(s):